Last reviewed · How we verify

Tryptyr — Competitive Intelligence Brief

Tryptyr (ACOLTREMON) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TRPM8 Thermoreceptor Agonist [EPC]. Area: Ophthalmology.

marketed TRPM8 Thermoreceptor Agonist [EPC] Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Tryptyr (ACOLTREMON) — Alcon Labs Inc. Tryptyr works by modulating the function of the lacrimal gland to increase tear production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tryptyr TARGET ACOLTREMON Alcon Labs Inc marketed TRPM8 Thermoreceptor Agonist [EPC] 2025-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TRPM8 Thermoreceptor Agonist [EPC] class)

  1. Alcon Labs Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tryptyr — Competitive Intelligence Brief. https://druglandscape.com/ci/acoltremon. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: